Cargando…
Overexpression of colorectal cancer oncogene CHRDL2 predicts a poor prognosis
Bone morphogenetic proteins (BMPs) both promote and suppress tumorigenesis, and multiple BMP antagonists reportedly contribute to cancer progression. In this study, we demonstrated that the BMP antagonist Chordin-like 2 (CHRDL2) is upregulated in colorectal cancer (CRC) tissues, and that CHRDL2 leve...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5355280/ https://www.ncbi.nlm.nih.gov/pubmed/28009989 http://dx.doi.org/10.18632/oncotarget.14039 |
_version_ | 1782515520302481408 |
---|---|
author | Sun, Jian Liu, Xuan Gao, Hong Zhang, Long Ji, Qing Wang, Ziyuan Zhou, Lihong Wang, Yan Sui, Hua Fan, Zhongze Li, Qi |
author_facet | Sun, Jian Liu, Xuan Gao, Hong Zhang, Long Ji, Qing Wang, Ziyuan Zhou, Lihong Wang, Yan Sui, Hua Fan, Zhongze Li, Qi |
author_sort | Sun, Jian |
collection | PubMed |
description | Bone morphogenetic proteins (BMPs) both promote and suppress tumorigenesis, and multiple BMP antagonists reportedly contribute to cancer progression. In this study, we demonstrated that the BMP antagonist Chordin-like 2 (CHRDL2) is upregulated in colorectal cancer (CRC) tissues, and that CHRDL2 levels correlate with clinical features of CRC patients, including tumor size, TNM staging, and tumor differentiation. In addition, survival rate and Cox proportional hazards model analyses showed that high CHRDL2 levels correlate with a poor prognosis in CRC. Moreover, CHRDL2 promoted CRC cell proliferation in vitro and in vivo, perhaps through up-regulation of Cyclin D1 and down-regulation of P21. Co-immunoprecipitation assays showed that CHRDL2 bound to BMPs, which inhibited p-Smad1/5, thereby promoting CRC cell proliferation and inhibiting apoptosis. These results suggest CHRDL2 could serve as a biomarker of poor prognosis in CRC, and provide evidence that CHRDL2 acts as an oncogene in human CRC, making it a novel potential therapeutic target. |
format | Online Article Text |
id | pubmed-5355280 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Impact Journals LLC |
record_format | MEDLINE/PubMed |
spelling | pubmed-53552802017-04-26 Overexpression of colorectal cancer oncogene CHRDL2 predicts a poor prognosis Sun, Jian Liu, Xuan Gao, Hong Zhang, Long Ji, Qing Wang, Ziyuan Zhou, Lihong Wang, Yan Sui, Hua Fan, Zhongze Li, Qi Oncotarget Research Paper Bone morphogenetic proteins (BMPs) both promote and suppress tumorigenesis, and multiple BMP antagonists reportedly contribute to cancer progression. In this study, we demonstrated that the BMP antagonist Chordin-like 2 (CHRDL2) is upregulated in colorectal cancer (CRC) tissues, and that CHRDL2 levels correlate with clinical features of CRC patients, including tumor size, TNM staging, and tumor differentiation. In addition, survival rate and Cox proportional hazards model analyses showed that high CHRDL2 levels correlate with a poor prognosis in CRC. Moreover, CHRDL2 promoted CRC cell proliferation in vitro and in vivo, perhaps through up-regulation of Cyclin D1 and down-regulation of P21. Co-immunoprecipitation assays showed that CHRDL2 bound to BMPs, which inhibited p-Smad1/5, thereby promoting CRC cell proliferation and inhibiting apoptosis. These results suggest CHRDL2 could serve as a biomarker of poor prognosis in CRC, and provide evidence that CHRDL2 acts as an oncogene in human CRC, making it a novel potential therapeutic target. Impact Journals LLC 2016-12-20 /pmc/articles/PMC5355280/ /pubmed/28009989 http://dx.doi.org/10.18632/oncotarget.14039 Text en Copyright: © 2017 Sun et al. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Paper Sun, Jian Liu, Xuan Gao, Hong Zhang, Long Ji, Qing Wang, Ziyuan Zhou, Lihong Wang, Yan Sui, Hua Fan, Zhongze Li, Qi Overexpression of colorectal cancer oncogene CHRDL2 predicts a poor prognosis |
title | Overexpression of colorectal cancer oncogene CHRDL2 predicts a poor prognosis |
title_full | Overexpression of colorectal cancer oncogene CHRDL2 predicts a poor prognosis |
title_fullStr | Overexpression of colorectal cancer oncogene CHRDL2 predicts a poor prognosis |
title_full_unstemmed | Overexpression of colorectal cancer oncogene CHRDL2 predicts a poor prognosis |
title_short | Overexpression of colorectal cancer oncogene CHRDL2 predicts a poor prognosis |
title_sort | overexpression of colorectal cancer oncogene chrdl2 predicts a poor prognosis |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5355280/ https://www.ncbi.nlm.nih.gov/pubmed/28009989 http://dx.doi.org/10.18632/oncotarget.14039 |
work_keys_str_mv | AT sunjian overexpressionofcolorectalcanceroncogenechrdl2predictsapoorprognosis AT liuxuan overexpressionofcolorectalcanceroncogenechrdl2predictsapoorprognosis AT gaohong overexpressionofcolorectalcanceroncogenechrdl2predictsapoorprognosis AT zhanglong overexpressionofcolorectalcanceroncogenechrdl2predictsapoorprognosis AT jiqing overexpressionofcolorectalcanceroncogenechrdl2predictsapoorprognosis AT wangziyuan overexpressionofcolorectalcanceroncogenechrdl2predictsapoorprognosis AT zhoulihong overexpressionofcolorectalcanceroncogenechrdl2predictsapoorprognosis AT wangyan overexpressionofcolorectalcanceroncogenechrdl2predictsapoorprognosis AT suihua overexpressionofcolorectalcanceroncogenechrdl2predictsapoorprognosis AT fanzhongze overexpressionofcolorectalcanceroncogenechrdl2predictsapoorprognosis AT liqi overexpressionofcolorectalcanceroncogenechrdl2predictsapoorprognosis |